Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (AU:TLX)
:TLX
TLX Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TLX Stock 12 Month Forecast
Average Price Target
AU$33.86
▲(61.45%Upside)
| Highest Price TargetAU$36.00 | Average Price TargetAU$33.86 | Lowest Price TargetAU$29.13 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
AU$22.5
Hold
7.30%
Upside
Downgraded
07/24/25
Telix Pharmaceuticals Ltd. demonstrates robust growth and strategic expansion plans, which are its main strengths. However, weak technical indicators and high valuation pose significant risks. The stock's potential is largely dependent on successful global expansion and effective cash flow management.
Jefferies
AU$34
Buy
62.14%
Upside
Reiterated
07/23/25
Bell Potter
AU$34
Buy
62.14%
Upside
Reiterated
07/23/25
UBS
AU$36
Buy
71.67%
Upside
Reiterated
07/23/25
Jarden
AU$29.14
Buy
38.96%
Upside
Reiterated
07/22/25
TD Cowen
AU$35
Buy
66.91%
Upside
Reiterated
07/22/25
Telix Pharmaceuticals: Strong Financial Performance and Growth Potential Drive Buy RatingWe believe there is likely to be some impact on Illuccix revenue by the loss of traditional pass through status (TPT) on July 1, after which it will have separate reimbursement coverage (note here). While the CMS new rule will only impact the Medicare Fee-For- Service patients (~20% of prostate cancer market), the rule requires reimbursement based on MUC pricing as opposed to a typical discount to WAC. As was seen with Lantheus' Pylarify, the MUC is typically 30-40% lower than the WAC or ASP, which could result in a slight impact to Q3 and Q4 sales.
Wilsons
AU$35
Buy
66.91%
Upside
Reiterated
05/08/25
Taylor Collison
AU$19.61
Buy
-6.49%
Downside
Reiterated
08/26/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
AU$22.5
Hold
7.30%
Upside
Downgraded
07/24/25
Telix Pharmaceuticals Ltd. demonstrates robust growth and strategic expansion plans, which are its main strengths. However, weak technical indicators and high valuation pose significant risks. The stock's potential is largely dependent on successful global expansion and effective cash flow management.
Jefferies
AU$34
Buy
62.14%
Upside
Reiterated
07/23/25
Bell Potter
AU$34
Buy
62.14%
Upside
Reiterated
07/23/25
UBS
AU$36
Buy
71.67%
Upside
Reiterated
07/23/25
Jarden
AU$29.14
Buy
38.96%
Upside
Reiterated
07/22/25
TD Cowen
AU$35
Buy
66.91%
Upside
Reiterated
07/22/25
Telix Pharmaceuticals: Strong Financial Performance and Growth Potential Drive Buy RatingWe believe there is likely to be some impact on Illuccix revenue by the loss of traditional pass through status (TPT) on July 1, after which it will have separate reimbursement coverage (note here). While the CMS new rule will only impact the Medicare Fee-For- Service patients (~20% of prostate cancer market), the rule requires reimbursement based on MUC pricing as opposed to a typical discount to WAC. As was seen with Lantheus' Pylarify, the MUC is typically 30-40% lower than the WAC or ASP, which could result in a slight impact to Q3 and Q4 sales.
Wilsons
AU$35
Buy
66.91%
Upside
Reiterated
05/08/25
Taylor Collison
AU$19.61
Buy
-6.49%
Downside
Reiterated
08/26/24
Best Analysts Covering Telix Pharmaceuticals
1 Month
xxx
Success Rate
11/14 ratings generated profit
Average Return
+10.72%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 78.57% of your transactions generating a profit, with an average return of +10.72% per trade.
3 Months
xxx
Success Rate
12/14 ratings generated profit
Average Return
+33.48%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +33.48% per trade.
1 Year
Success Rate
17/19 ratings generated profit
Average Return
+66.30%
reiterated a buy rating 4 days ago
Copying Steven Wheen's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +66.30% per trade.
2 Years
xxx
Success Rate
17/19 ratings generated profit
Average Return
+142.43%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 89.47% of your transactions generating a profit, with an average return of +142.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TLX Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
8
18
15
14
14
Buy
1
0
0
0
0
Hold
0
0
1
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
18
16
15
16
Each month's total comprises the sum of three months' worth of ratings.
TLX Financial Forecast
TLX Stock Forecast FAQ
What is AU:TLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 33.86.
What is AU:TLX’s upside potential, based on the analysts’ average price target?
Telix Pharmaceuticals Ltd. has 61.45% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Telix Pharmaceuticals Ltd. a Buy, Sell or Hold?
Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Telix Pharmaceuticals Ltd.’s share price target?
The average share price target for Telix Pharmaceuticals Ltd. is 33.86. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is AU$36.00 ,and the lowest forecast is AU$29.13. The average share price target represents 61.45% Increase from the current price of AU$20.97.
The highest analyst share price target is AU$36.00 ,and the lowest forecast is AU$29.13. The average share price target represents 61.45% Increase from the current price of AU$20.97.
What do analysts say about Telix Pharmaceuticals Ltd.?
Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of Telix Pharmaceuticals Ltd.?
To buy shares of AU:TLX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.